论文部分内容阅读
移植后淋巴增殖性疾病(post-transplant lymphoproliferative disorders,PTLD)是器官和造血干细胞移植后的严重并发症之一,PTLD在异基因造血干细胞移植(allo-HSCT)中发生率为0~25%,几乎所有的早期PTLD与EBV病毒感染有关,高发于去T细胞移植或预处理方案中采用抗胸腺细胞球蛋白(ATG)、无关和半相合移植患者中。部分
Post-transplant lymphoproliferative disorders (PTLD) are one of the most serious complications after organ and hematopoietic stem cell transplantation. The incidence of PTLD in allogeneic hematopoietic stem cell transplantation (allo-HSCT) is 0-25% Almost all of the early PTLDs are associated with EBV infection and are predominant in patients who have been treated with antithymocyte globulin (ATG), unrelated and semi-co-transplantation patients for de-T cell transplantation or preconditioning regimens. section